Updates are available Correction dated 2022-09-23
Click to view Correction: https://doi.org/10.1038/s41586-022-05358-w
-
Authors
Kedmi, Ranit
Najar, Tariq A.
Mesa, Kailin R. http://orcid.org/0000-0003-4452-9048
Grayson, Allyssa
Kroehling, Lina
Hao, Yuhan
Hao, Stephanie http://orcid.org/0000-0002-1700-9699
Pokrovskii, Maria
Xu, Mo
Talbot, Jhimmy
Wang, Jiaxi
Germino, Joe http://orcid.org/0000-0003-3939-3342
Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Satpathy, Ansuman T. http://orcid.org/0000-0002-5167-537X
Anderson, Mark S. http://orcid.org/0000-0002-3093-4758
Laufer, Terri M.
Aifantis, Iannis
Bartleson, Juliet M.
Allen, Paul M. http://orcid.org/0000-0003-3796-6047
Paidassi, Helena
Gardner, James M. http://orcid.org/0000-0003-3470-9520
Stoeckius, Marlon
Littman, Dan R. http://orcid.org/0000-0002-2850-8688
- License Information
-
More Information
Article History
Received: 8 November 2021
Accepted: 8 July 2022
First Online: 7 September 2022
Change Date: 23 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05358-w
Competing interests
: D.R.L. consults and has equity interest in Chemocentryx, Vedanta, Immunai and Pfizer Pharmaceuticals. All other authors declare no competing interests.
